Lonrf3, also known as a member of the E3 ubiquitin-protein ligase family, is involved in the process of ubiquitination, which plays a crucial role in regulating protein degradation, cell cycle, and various cellular signaling pathways [2]. Dysregulation of such E3 ligases can have implications for cancer development.

In breast cancer, Lonrf3 was screened as one of the prognostic signature genes related to M2-like tumor-associated macrophages (M2-like TAMs). A RiskScore model based on these genes was developed, and it was found that the mRNA expression levels of Lonrf3 were significantly different in control and breast cancer cell lines, suggesting its potential as a therapeutic target [1].

In pancreatic cancer, among differentially expressed E3 ubiquitin-protein ligase genes, Lonrf3 was identified to have prognostic significance, along with other genes and clinical parameters. This indicates its possible role in pancreatic cancer progression [2].

In conclusion, Lonrf3, as an E3 ubiquitin-protein ligase, is involved in important cellular regulatory pathways. Its differential expression in breast and pancreatic cancer cell lines suggests its potential significance in these disease areas, providing potential targets for further research and therapeutic development.